Page 28 - Sciences Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

  Curaleaf to Enter European Cannabis Market with Acquisition of EMMAC Life Sciences Limited - Europe's Leading Independent Cannabis Company EMMAC Brings the Largest Vertically Integrated Independent Cannabis Company in Europe with a Presence in Key European Medical Cannabis Markets, Including the United Kingdom, Germany, Italy, Spain, and Portugal With the European Population of Nearly 748 Million 1, the Potential Addressable Market is More than Twice the Size of U.S. Market     10 March, London. EMMAC Life Sciences Group, Europe's large...

Curaleaf Reports Record Fourth Quarter and Fiscal Year End 2020 Financial and Operational Results Record Fiscal Year and Fourth Quarter 2020 Pro Forma Revenue(1)(2) of $767.1 Million and $238.8 Million, Respectively Record Fiscal Year and Fourth Quarter 2020 Managed Revenue(1) of $653.0 Million, up 161% from 2019 and $233.3 Million, up 186% from 2019, Respectively Record Fiscal Year and Fourth Quarter 2020 Adjusted EBITDA(1) of $144.1 Million up 456% from 2019 and $53.8 Million up 289% from 2019, Respectively, as Operations Across 23 States Continue to Scale Raised $289.8 Million of Net Proce...

MJH Life Sciences' President and Chief Executive Officer Michael J. Hennessy Jr. has been recognized by MM+M as one of the most influential leaders under the age of 40 in the pharma and health care marketing sectors.PHOTO COURTESY OF MJH LIFE SCIENCES × MJH Life Sciences' President and Chief Executive Officer Michael J. Hennessy Jr. has been recognized by MM+M as one of the most influential leaders under the age of 40 in the pharma and health care marketing sectors.PHOTO COURTESY OF MJH LIFE SCIENCES MJH Life Sciences’ President and Chief Executive Officer Michael J. Hennessy Jr. h...

26 January 2021     FastForward Innovations Ltd, the AIM quoted company focusing on making investments in fast growing and industry leading businesses, notes the following announcement released today concerning investee company EMMAC Life Sciences ('EMMAC'). FastForward has a 2.3% interest in the issued stock of EMMAC.     EMMAC Life Sciences Group and Boiron selected for French Medical Cannabis trial Only European Company selected by the French Agency for the Safety of Medicines and Health Products (ANSM)   ...

CAUTIONARY STATEMENT All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Group. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-l...